

## Lipum and NorthX Biologics enter into new strategic manufacturing alliance

**Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases today announces that it has entered into a manufacturing alliance with NorthX Biologics AB, a Contract Development and Manufacturing Organisation (CDMO).**

Under this agreement NorthX will manufacture Lipum's lead asset, SOL-116, a humanized antibody, for use in a phase II clinical trial. SOL-116 is transferred from the current manufacturer to NorthX which will lead to cost and time savings with high quality.

Ola Sandborgh, CEO of Lipum said *"We are delighted to be partnering with NorthX and it represents an important step as we move forward into our phase II trial. NorthX's capabilities are a great fit and provide a cost effective one-stop-shop for both drug substance and sterile fill finish drug product. I am very much looking forward to the collaboration and bringing this therapy a step closer to patients"*.

Janet Hoogstraate, CEO of NorthX Biologics added *"We are excited to be working on SOL-116 and look forward to adding our expertise and experience in the GMP manufacture of advanced biologics to the ultimate benefit of patients"*.

### **About NorthX Biologics AB**

NorthX Biologics, a leading Nordic Development and Manufacturing Organization, has expertise in producing cell and gene therapies, proteins, vaccines, other advanced biologics. With two sites in Sweden and headquartered in Matfors, the team has been manufacturing biologics to GMP standards since 1992. In 2021 NorthX was designated a national innovation hub for advanced therapies and vaccines and has the ambition to become a leading cell and gene therapy manufacturer and partner for innovative drug development companies. For more information see [www.nxbio.com](http://www.nxbio.com).

### **Contacts**

Ola Sandborgh, CEO

[ola.sandborgh@lipum.se](mailto:ola.sandborgh@lipum.se)

+46 72 218 80 21

Web: [www.lipum.se](http://www.lipum.se)

**PRESS RELEASE**

18 April 2024 15:30:00 CEST



**About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

**Attachments**

[Lipum and NorthX Biologics enter into new strategic manufacturing alliance](#)